STAT

Opinion: Multi-target drugs should be in the pharma pipeline along with precision drugs

Three of the most effective and widely used drugs — acetaminophen, aspirin, and ibuprofen — are multi-target drugs. We need others like them for complex diseases such as cancer and…
Source: Quinn Rooney/Getty Images

Precision medicine — providing the right treatment, for the right patient, at the right time — is saving lives. The use of therapies that home in on single targets is helping beat tough-to-treat diseases that were often deadly in the past.

But we’re overlooking another class of extremely important and promising candidates: multi-target drugs. Discounting these drugs is a disservice to patients and a missed opportunity for U.S.-based companies to bring potentially game-changing drugs to market.

Most drugs on the market today take aim at a single biologic substance, like a protein or enzyme. In contrast, multi-target drugs hit several targets, which is often necessary to do in order to yield a therapeutic effect in complex diseases.

While single-target drugs were once viewed as desirable largely because of the concern that “off-target” effects

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
An FDA Advisory Panel Is Reviewing Aimmune’s Peanut Allergy Therapy. Here’s What’s Happening
STAT's @adamfeuerstein will be watching watching a live feed of today’s FDA advisory panel to discuss a peanut allergy treatment. Follow along for updates.
STAT8 min read
‘There’s No Such Thing As Anonymity’: With Consumer DNA Tests, Sperm Banks Reconsider Long-held Promises To Donors
For generations, it was a basic tenet of donating sperm: Clinics could forever protect their clients’ identities. But, increasingly, donor anonymity is dead.
STAT1 min readScience
Listen: Pelosi’s Drug Pricing Plan, Moderna’s MRNA Drug Factories, And A DIY Disease Cure
House Speaker Nancy Pelosi’s drug pricing plan is aggressive, but is it viable? What’s it like to cure your own rare disease? All that and more on the new episode…